{"database": "lobbying", "table": "lobbying_activities", "rows": [[2819799, "6702f07a-360d-4b9a-85ff-00afa5e530c4", "Q2", "MARSHALL & POPP, LLC", 401105121, "GENENTECH, INC.", 2022, "second_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2022-07-15T00:51:16-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2819799"], "units": {}, "query_ms": 33.73607899993658, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}